TY  - JOUR
A1  - Cavalcante, Deivyd Vieira Silva
A1  - de Oliveira, Lilia Maria Lima
A1  - Husain, Noor
A1  - Mendes, Beatriz Ximenes
A1  - Santos, Ana Clara Felix de Farias
A1  - Borrigueiro, Luciana
A1  - Rosa, Lyria de Oliveira
A1  - Ndikuryayo, Christian
A1  - Amorim, Sarah Soares
A1  - Mohan, Lalit
A1  - Lopes, Fabiana Castro Porto Silva
IS  - 2
Y1  - 2026/02//
UR  - http://doi.org/10.1016/j.diagmicrobio.2025.117160
TI  - Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis
JF  - Diagnostic Microbiology and Infectious Disease
N2  - Background
Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition.
Methods
PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes.
Results
Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81?90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09?77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84?58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97?43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81?28.25).
Conclusions
These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks.
ID  - uneatlantico17868
VL  - 114
SN  - 07328893
AV  - none
ER  -